Remission in Adults With Mild-to-moderate Asthma in Thailand

Thammasat University

Status: Not yet enrolling

Conditions: Asthma; Mild-to-moderate Asthma; Asthma Control Level

Treatments: Other: Fractional exhaled nitric oxide (FeNO) test; Other: Spirometry; Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires; Other: Blood eosinophil count (BEC)

Study type: Observational

Funder types: Other

Identifiers

NCT07351916

MTU-EC-IM-0-282/68

Details and patient eligibility

About

The goal of this observational study is to determine the prevalence of remission among adults with mild-to-moderate asthma, as well as the factors associated with remission in Thailand.

The main question the study aims to answer is:

What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete a questionnaire on asthma symptoms and undergo pulmonary function testing and a blood test once.

Full description

This study is a cross-sectional study. Thai patients aged 18 years or older with mild-to-moderate asthma are included in the study. Participants will complete two questionnaires about asthma control: the Global Initiative for Asthma (GINA) and the Asthma Control Test (ACT), and will perform spirometry, a fractional exhaled nitric oxide (FeNO) test, and blood eosinophil counts (BEC).

GINA and ACT are questionnaires used to assess the level of asthma control.

Enrollment: 289 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• mild-to-moderate asthma
• age 18 years or older

Exclusion criteria

• inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test

Trial design

289 participants in 1 patient group

Mild-to-moderate asthma

Description:

Patients aged 18 years or older with mild-to-moderate asthma. Mild asthma refers to asthma patients who experience symptoms \<3 times per week, have preserved lung function (FEV₁ or PEF \>80% of predicted), and whose symptoms can be adequately controlled with low-dose inhaled corticosteroids (low-dose ICS) alone, without the need for long-acting bronchodilators or other controller medications. Moderate asthma refers to asthma patients who have symptoms \>4-5 days per week or experience nocturnal asthma symptoms \>1 per week, and who require treatment with medium-dose inhaled corticosteroids (medium-dose ICS) or low-dose ICS in combination with a long-acting β₂-agonist (low-dose ICS/LABA) to achieve symptom control and prevent exacerbations.

Treatment:

Other: Blood eosinophil count (BEC)

Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires

Other: Spirometry

Other: Fractional exhaled nitric oxide (FeNO) test